Insulin resistance in schizophrenia, major depression, and bipolar disorder

Insulin Resistance Syndrome and Neuropsychiatric Disease

Volumn , Issue , 2008, Pages 49-86

  Lindley, Steven E ^a   Schröder, Carmen M ^a   O’hara, Ruth ^a   Fazio, Sergio ^b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85078989812     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.3109/9781420091465-6     Document Type: Chapter

References (148)

1. Hennekens CH, Hennekens AR, Hollar D, et al. Schizophrenia and increased risks of cardiovascular disease. Am Heart J 2005; 150:1115-1121.
2. Saari KM, Lindeman SM, Viilo KM, et al. A 4-fold risk of metabolic syndrome in patients with schizophrenia: the Northern Finland 1966 Birth Cohort study. J Clin Psychiatry 2005; 66:559-563.
3. Hagg S, Lindblom Y, Mjorndal T, et al. High prevalence of the metabolic syndrome among a Swedish cohort of patients with schizophrenia. Int Clin Psychopharmacol 2006; 21:93-84.
4. Mcevoy JP, Meyer JM, Goff DC, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 2005; 80:19-32.
5. Meyer JM, Nasrallah HA, Mcevoy JP, et al. The Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE) Schizophrenia Trial: clinical comparison of subgroups with and without the metabolic syndrome. Schizophr Res 2005; 80:9-18.
6. Citrome L, Jaffe A, Levine J, et al. Incidence, prevalence, and surveillance for diabetes in New York State psychiatric hospitals, 1997-2004. Psychiatr Serv 2006; 57:1132-1139.
7. Mcdonald M, Hertz RP, Lustik MB, et al. Healthcare spending among community-dwelling adults with schizophrenia. Am J Manag Care 2005; 11:S242-S247.
8. Kohen D. Diabetes mellitus and schizophrenia: historical perspective. Br J Psychiatry Suppl 2004; 47:S64-S66.
9. Henderson DC. Atypical antipsychotic-induced diabetes mellitus: how strong is the evidence? CNS Drugs 2002; 16:77-89.
10. Leadbetter R, Shutty M, Pavalonis D, et al. Clozapine-induced weight gain: prevalence and clinical relevance. Am J Psychiatry1992; 149:68-72.
11. Allison DB, Casey DE. Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry 2001; 62(suppl7): 22-31.
12. Melkersson K, Dahl Ml. Adverse metabolic effects associated with atypical antipsychotics: literature review and clinical implications. Drugs; 2004; 64:701-723.
13. Sernyak MJ, Leslie DL, Alarcon RD, et al. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry 2002; 159:561-566.
14. Baptista T, Martinez J, Lacruz A, et al. Metformin for prevention of weight gain and insulin resistance with olanzapine: a doubleblind placebo-controlled trial. Can J Psychiatry 2006; 51: 192-196.
15. Henderson DC, Cagliero E, Copeland PM, et al. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. Arch Gen Psychiatry2005; 62:19-28.
16. Wirshing DA. Schizophrenia and obesity: impact of antipsychotic medications. 2004; J Clin Psychiatry 65(suppl 18):13-26.
17. Lafayette JM, Pirl WF, Henderson DC. Low-dose clozapine and diabetic ketoacidosis. Psychosomatics 2003; 44:249-252.
18. Ryan MC, Collins P, Thakore JH. Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry 2003; 160:284-289.
19. Arranz B, Rosel P, Ramirez N, et al. Insulin resistance and increased leptin concentrations in noncompliant schizophrenia patients but not in antipsychotic-naive first-episode schizophrenia patients. J Clin Psychiatry 2004; 65:1335-1342.
20. Mukherjee S, Schnur DB, Reddy R. Family history of type 2 diabetes in schizophrenic patients. Lancet 1989; 1:495.
21. Homel P, Casey D, Allison DB. Changes in body mass index for individuals with and without schizophrenia, 1987-1996. Schizophr Res 2002; 55:277-284.
22. Dickerson FB, Brown CH, Daumit GL, et al. Health status of individuals with serious mental illness. Schizophr Bull 2006; 32:584-589.
23. Thakore JH, Mann JN, Vlahos I, et al. Increased visceral fat distribution in drug-naive and drug-free patients with schizophrenia. Int J Obes Relat Metab Disord 2002; 26:137-141.
24. Brown S, Birtwistle J, Roe L, et al. The unhealthy lifestyle of people with schizophrenia. Psychol Med 1999; 29:697-701.
25. Mccreadie RG. Diet, smoking and cardiovascular risk in people with schizophrenia: descriptive study. Br J Psychiatry 2003; 183:534-539.
26. Strassnig M, Singh Brar J, Ganguli R. Dietary fatty acid and antioxidant intake in community-dwelling patients suffering from schizophrenia. Schizophr Res 2005; 76:343-351.
27. Henderson DC, Borba CP, Daley TB, et al. Dietary intake profile of patients with schizophrenia. Ann Clin Psychiatry 2006; 18:99-105.
28. Sharpe JK, Stedman TJ, Byrne NM, et al. Energy expenditure and physical activity in clozapine use: implications for weight management. Aust N Z J Psychiatry 2006; 40:810-814.
29. Sharpe JK, Byrne NM, Stedman TJ, et al. Resting energy expenditure is lower than predicted in people taking atypical antipsychotic medication. J Am Diet Assoc 2005; 105:612-615.
30. Arjona AA, Zhang SX, Adamson B, et al. An animal model of antipsychotic-induced weight gain. Behav Brain Res 2004; 152:121-127.
31. Gothelf D, Falk B, Singer P, et al. Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine. Am J Psychiatry 2002; 159:1055-1057.
32. Dallman, MF, et al. Corticosteroids and the control of function in the hypothalamo-pituitary-adrenal (HPA) axis. Annals of the New York Academy of Sciences 1994; 746:22-31.
33. Rosmond R. Role of stress in the pathogenesis of the metabolic syndrome. Psychoneuroendocrinology 2005; 30:1-10 (review).
34. Morris D, Grossman A. The medical management of Cushing’s syndrome. Ann N Y Acad Sci 2002; 970:119-133.
35. Dinan TG. Stress and the genesis of diabetes mellitus in schizophrenia. Br J Psychiatry Suppl 2004; 47:S72-S75.
36. Dinneen S, Alzaid A, Miles J, et al. Metabolic effects of the nocturnal rise in cortisol on carbohydrate metabolism in normal humans. J Clin Invest 1993; 92:2283-2290.
37. Brown ES, Varghese FP, Mcewen BS. Association of depression with medical illness: does cortisol play a role? Biol Psychiatry2004; 55:1-9.
38. Mooy JM, De Vries H, Grootenhuis PA, et al. Major stressful life events in relation to prevalence of undetected type 2 diabetes: the Hoorn Study. Diabetes Care 2000; 23:197-201.
39. Shiloah E, Witz S, Abramovitch Y, et al. Effect of acute psychotic stress in nondiabetic subjects on beta-cell function and insulin sensitivity. Diabetes Care 2003; 26:1462-1467.
40. Marx CE, Lieberman JA. Psychoneuroendocrinology of schizophrenia Psychiatr Clin North Am 1998; 21:413-434.
41. Siris SG. Suicide and schizophrenia. J Psychopharmacol 2001; 15:127-135.
42. Ryan MC, Collins P, Thakore JH. Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry 2003; 160:284-289.
43. Pariante CM, Vassilopoulou K, Velakoulis D, et al. Pituitary volume in psychosis. Br J Psychiatry 2004; 185:5-10.
44. Nasrallah HA, Meyer JM, Goff DC, et al. Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophr Res 2006; 86:15-22.
45. Poyurovsky M, Pashinian A, Gil-Ad I, et al. Olanzapine-induced weight gain in patients with first-episode schizophrenia: a doubleblind, placebo-controlled study of fluoxetine addition. Am J Psychiatry 2002; 159:1058-1060.
46. Floris M, Lejeune J, Deberdt W. Effect of amantadine on weight gain during olanzapine treatment. Eur Neuropsychopharmacol2001; 11:181-182.
47. Ko Yh, Joe Sh, Jung IK, et al. Topiramate as an adjuvant treatment with atypical antipsychotics in schizophrenic patients experiencing weight gain. Clin Neuropharmacol 2005; 28:169-175.
48. Baptista T, Martinez J, Lacruz A, et al. Metformin for prevention of weight gain and insulin resistance with olanzapine: a doubleblind placebo-controlled trial. Can J Psychiatry 2006; 51:192-196.
49. Su KP, Wu PL, Pariante CM. A crossover study on lipid and weight changes associated with olanzapine and risperidone. Psychopharmacology (Berl) 2005; 183:383-386.
50. Kwon JS, Choi JS, Bahk WM, et al. Weight management program for treatment-emergent weight gain in olanzapine-treated patients with schizophrenia or schizoaffective disorder: a 12-week randomized controlled clinical trial. J Clin Psychiatry 2006; 67:547-553.
51. Weber M, Wyne K. A cognitive/behavioral group intervention for weight loss in patients treated with atypical antipsychotics. Schizophr Res 2006; 83:95-101
52. Musselman DL, Betan E, Larsen H, et al. Relationship of depression to diabetes types 1 and 2: epidemiology, biology, and treatment. Biol Psychiatry 2003; 54:317-329.
53. Lett HS, Blumenthal JA, Babyak MA, et al. Depression as a risk factor for coronary artery disease: evidence, mechanisms, and treatment. Psychosom Med 2004; 66:305-315.
54. Murray C, Lopez A. The global burden of disease. Cambridge, MA: Harvard University Press, 1996.
55. Greenberg PE, Kessler RC, Birnbaum HG, et al. The economic burden of depression in the United States: how did it change between 1990 and 2000? J Clin Psychiatry 2003; 64:1465-1475.
56. Lerner D, Adler DA, Chang H, et al. Unemployment, job retention, and productivity loss among employees with depression. Psychiatr Serv 2004; 55:1371-1378.
57. Stein MB, Cox BJ, Afifi TO, et al. Does co-morbid depressive illness magnify the impact of chronic physical illness? A population-based perspective. Psychol Med 2006; 36:587-596.
58. Katon WJ. Clinical and health services relationships between major depression, depressive symptoms, and general medical illness. Biol Psychiatry 2003; 54:216-226.
59. Ciechanowski PS, Katon WJ, Russo JE. Depression and diabetes: impact of depressive symptoms on adherence, function, and costs. Arch Intern Med 2000; 160:3278-3285.
60. Egede LE, Zheng D, Simpson K. Comorbid depression is associated with increased health care use and expenditures in individuals with diabetes. Diabetes Care 2002; 25:464-470.
61. Ramasubbu R. Insulin resistance: A metabolic link between depressive disorder and atherosclerotic vascular diseases. Med Hypotheses 2002; 59:537-551.
62. Okamura F, Tashiro A, Utumi A, et al. Insulin resistance in patients with depression and its changes during the clinical course of depression: minimal model analysis. Metabolism 2000; 49:1255-1260.
63. Lawlor DA, Smith GD, Ebrahim S. Association of insulin resistance with depression: cross sectional findings from the British Women’s Heart and Health Study. BMJ 2003; 327:1383-1384.
64. Lawlor DA, Ben-Shlomo Y, Ebrahim S, et al. Insulin resistance and depressive symptoms in middle aged men: findings from the Caerphilly prospective cohort study. BMJ 2005; 330:705-706.
65. Timonen M, Rajala U, Jokelainen J, et al. Depressive symptoms and insulin resistance in young adult males: results from the Northern Finland 1966 birth cohort. Mol Psychiatry 2006; 11:929-933.
66. Timonen M, Laakso M, Jokelainen J, et al. Insulin resistance and depression: cross sectional study. BMJ 2005; 330:17-18.
67. Anderson RJ, Freedland KE, Clouse RE, et al. The prevalence of comorbid depression in adults with diabetes: a meta-analysis. Diabetes Care 2001; 24:1069-1078.
68. Nichols GA, Brown JB. Unadjusted and adjusted prevalence of diagnosed depression in type 2 diabetes. Diabetes Care 2003; 26:744-749.
69. Rasgon NL, Rao RC, Hwang S, et al. Depression in women with polycystic ovary syndrome: clinical and biochemical correlates. J Affect Disord 2003; 74:299-304.
70. Freeman MP. Depression and hormonal contraception. JAMA2001; 286:671-672.
71. Zimmermann U, Kraus T, Himmerich H, et al. Epidemiology, implications and mechanisms underlying drug-induced weight gain in psychiatric patients. J Psychiatr Res 2003; 37:193-220.
72. Kazes M, Danion JM, Grange D, et al. Eating behaviour and depression before and after antidepressant treatment: a prospective, naturalistic study. J Affect Disord 1994; 30:193-207.
73. Fava M, Judge R, Hoog SL, et al. Fluoxetine versus sertraline and paroxetine in major depressive disorder: changes in weight with long-term treatment. J Clin Psychiatry 2000; 61:863-867.
74. Kraus T, Haack M, Schuld A, et al. Body weight, the tumor necrosis factor system, and leptin production during treatment with mirtazapine or venlafaxine. Pharmacopsychiatry 2002; 35:220-225.
75. Gadde KM, Parker CB, Maner LG, et al. Bupropion for weight loss: an investigation of efficacy and tolerability in overweight and obese women. Obes Res 2001; 9:544-551.
76. Marken PA, Haykal RF, Fisher JN. Management of psychotropic-induced hyperprolactinemia. Clin Pharm 1992; 11:851-856.
77. Foss MC, Paula FJ, Paccola GM, et al. Peripheral glucose metabolism in human hyperprolactinaemia. Clin Endocrinol (Oxf)1995; 43:721-726.
78. Muldoon MF, Mackey RH, Korytkowski MT, et al. The metabolic syndrome is associated with reduced central serotonergic responsivity in healthy community volunteers. J Clin Endocrinol Metab 2006; 91:718-721.
79. Horacek J, Kuzmiakova M, Hoschl C, et al. The relationship between central serotonergic activity and insulin sensitivity in healthy volunteers. Psychoneuroendocrinology 1999; 24:785-797.
80. Potter Van Loon BJ, Radder JK, Frolich M, et al. Fluoxetine increases insulin action in obese nondiabetic and in obese noninsulin-dependent diabetic individuals. Int J Obes Relat Metab Disord 1992; 16:79-85.
81. Goodnick PJ, Henry JH, Buki VM. Treatment of depression in patients with diabetes mellitus. J Clin Psychiatry 1995; 56:128-136.
82. Kauffman RP, Castracane VD, White DL, et al. Impact of the selective serotonin reuptake inhibitor citalopram on insulin sensitivity, leptin and basal cortisol secretion in depressed and nondepressed euglycemic women of reproductive age. Gynecol Endocrinol 2005; 21:129-137.
83. Scherrer JF, Xian H, Bucholz KK, et al. A twin study of depression symptoms, hypertension, and heart disease in middle-aged men. Psychosom Med 2003; 65:548-557.
84. Chiba M, Suzuki S, Hinokio Y, et al. Tyrosine hydroxylase gene microsatellite polymorphism associated with insulin resistance in depressive disorder. Metabolism 2000; 49:1145-1149.
85. Ejchel TF, Araujo LM, Ramos LR, et al. Association of the apoli-poprotein A-IV: 360 Gln/His polymorphism with cerebrovascular disease, obesity, and depression in a Brazilian elderly population. Am J Med Genet B Neuropsychiatr Genet 2005; 135:65-68.
86. Van Rossum EF, Koper JW, Huizenga NA, et al. A polymorphism in the glucocorticoid receptor gene, which decreases sensitivity to glucocorticoids in vivo, is associated with low insulin and cholesterol levels. Diabetes 2002; 51:3128-3134.
87. Marti A, Ochoa MC, Sanchez-Villegas A, et al. Meta-analysis on the effect of the N363S polymorphism of the glucocorticoid receptor gene (GRL) on human obesity. BMC Med Genet 2006; 7:50.
88. Newman JC, Holden RJ. The ‘cerebral diabetes’ paradigm for unipolar depression. Med Hypotheses 1993; 41:391-408.
89. Holden RJ. The role of brain insulin in the neurophysiology of serious mental disorders: review. Med Hypotheses 1999; 52:193-200.
90. Ruhwinkel B, Tolle R. [Modified insulin treatment of therapy refractory depression]. Psychiatr Prax 1995; 22:64-67.
91. Carney RM, Rich MW, Tevelde A, et al. Major depressive disorder in coronary artery disease. Am J Cardiol 1987; 60:1273-1275.
92. Robinson RG, Starkstein SE. Current research in affective disorders following stroke. J Neuropsychiatry Clin Neurosci 1990; 2:1-14.
93. Sachs G, Spiess K, Moser G, et al. [Glycosylated hemoglobin and diabetes—self monitoring (compliance) in depressed and nondepressed type I diabetic patients]. Psychother Psychosom Med Psychol 1991; 41:306-312.
94. Baxter LR Jr., Phelps ME, Mazziotta JC, et al. Cerebral metabolic rates for glucose in mood disorders. Studies with positron emission tomography and fluorodeoxyglucose F 18. Arch Gen Psychiatry 1985; 42:441-447.
95. Drevets WC, Ongur D, Price JL. Neuroimaging abnormalities in the subgenual prefrontal cortex: implications for the pathophysiology of familial mood disorders. Mol Psychiatry 1998; 3:220-226, 190-191.
96. Brody AL, Saxena S, Mandelkern MA, et al. Brain metabolic changes associated with symptom factor improvement in major depressive disorder. Biol Psychiatry 2001; 50:171-178.
97. Woods SC, Porte D Jr., Bobbioni E, et al. Insulin: its relationship to the central nervous system and to the control of food intake and body weight. Am J Clin Nutr 1985; 42:1063-1071.
98. Unger JW, Moss AM, Livingston JN. Immunohistochemical localization of insulin receptors and phosphotyrosine in the brainstem of the adult rat. Neuroscience 1991; 42:853-861.
99. Gupta G, Azam M, Baquer NZ. Effect of experimental diabetes on the catecholamine metabolism in rat brain. J Neurochem 1992; 58:95-100.
100. Cheng B, Mattson MP. IGF-I and IGF-II protect cultured hippocampal and septal neurons against calcium-mediated hypoglycemic damage. J Neurosci 1992; 12:1558-1566.
101. Gerozissis K. Brain insulin: regulation, mechanisms of action and functions. Cell Mol Neurobiol 2003; 23:1-25.
102. Rasgon N, Jarvik GP, Jarvik L. Affective disorders and Alzheimer disease: a missing-link hypothesis. Am J Geriatr Psychiatry 2001; 9:444-445.
103. Rasgon N, Jarvik L. Insulin resistance, affective disorders, and Alzheimer’s disease: review and hypothesis. J Gerontol A Biol Sci Med Sci 2004; 59:178-83. [discussion 184-92].
104. Carpenter KM, Hasin DS, Allison DB, et al. Relationships between obesity and DSM-IV major depressive disorder, suicide ideation, and suicide attempts: results from a general population study. Am J Public Health 2000; 90:251-257.
105. Herva A, Laitinen J, Miettunen J, et al. Obesity and depression: results from the longitudinal Northern Finland 1966 Birth Cohort Study. Int J Obes (Lond) 2006; 30:520-527.
106. Bornstein SR, Schuppenies A, Wong ML, et al. Approaching the shared biology of obesity and depression: the stress axis as the locus of gene-environment interactions. Mol Psychiatry 2006; 11:892-902.
107. Babyak M, Blumenthal JA, Herman S, et al. Exercise treatment for major depression: maintenance of therapeutic benefit at 10 months. Psychosom Med 2000; 62:633-638.
108. Rasgon NL, Altshuler LI, Fairbanks L, et al. Reproductive function and risk for PCOS in women treated for bipolar disorder. Bipolar Disord 2005; 7:246-259.
109. Rasgon NL, Reynolds MF, Elman S, et al. Longitudinal evaluation of reproductive function in women treated for bipolar disorder. J Affect Disord 2005; 89:217-225.
110. Winokur A, Maislin G, Phillips JL, et al. Insulin resistance after oral glucose tolerance testing in patients with major depression. Am J Psychiatry 1988; 145:325-330.
111. De Filippis E, Cusi K, Ocampo G, et al. Exercise-induced improvement in vasodilatory function accompanies increased insulin sensitivity in obesity and type 2 diabetes mellitus. J Clin Endocrinol Metab 2006; 91:4903-4910.
112. Ernst C, Olson AK, Pinel JP, et al. Antidepressant effects of exercise: evidence for an adult-neurogenesis hypothesis?J Psychiatry Neurosci 2006; 31:84-92.
113. Duman RS. Neurotrophic factors and regulation of mood: role of exercise, diet and metabolism. Neurobiol Aging 2005; 26(suppl1):88-93.
114. Hendrickx H, Mcewen BS, Ouderaa F. Metabolism, mood and cognition in aging: the importance of lifestyle and dietary intervention. Neurobiol Aging 2005; 26(suppl1):1-5.
115. Alpert JE, Fava M, Uebelacker LA, et al. Patterns of axis I comorbidity in early-onset versus late-onset major depressive disorder. Biol Psychiatry 1999; 46:202-211.
116. Flanagan DE, Moore VM, Godsland IF, et al. Alcohol consumption and insulin resistance in young adults. Eur J Clin Invest 2000; 30:297-301.
117. Rimm EB, Williams P, Fosher K, et al. Moderate alcohol intake and lower risk of coronary heart disease: meta-analysis of effects on lipids and haemostatic factors. BMJ 1999; 319:1523-1528.
118. Lucas DL, Brown RA, Wassef M, et al. Alcohol and the cardiovascular system research challenges and opportunities. J Am Coll Cardiol 2005; 45:1916-1924.
119. Djousse L, Ellison RC, Beiser A, et al. Alcohol consumption and risk of ischemic stroke: The Framingham Study. Stroke 2002; 33:907-912.
120. Bjorntorp P. Visceral fat accumulation: the missing link between psychosocial factors and cardiovascular disease? J Intern Med1991; 230:195-201.
121. Rosengren A, Hawken S, Ounpuu S, et al. Association of psychosocial risk factors with risk of acute myocardial infarction in 11119 cases and 13648 controls from 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364:953-962.
122. Lupien SJ, Fiocco A, Wan N, et al. Stress hormones and human memory function across the lifespan. Psychoneuroendocrinology2005; 30:225-242.
123. Banki CM, Karmacsi L, Bissette G, et al. CSF corticotropinreleasing hormone and somatostatin in major depression: response to antidepressant treatment and relapse. Eur Neuro-psychopharmacol 1992; 2:107-113.
124. Gillespie CF, Nemeroff CB. Hypercortisolemia and depression. Psychosom Med 2005; 67(suppl):S26-S28.
125. Andrews RC, Walker BR. Glucocorticoids and insulin resistance: old hormones, new targets. Clin Sci (Lond) 1999; 96:513-523.
126. Hoyer S, Henneberg N, Knapp S, et al. Brain glucose metabolism is controlled by amplification and desensitization of the neuronal insulin receptor. Ann N Y Acad Sci 1996; 777:374-379.
127. Lowe B, Hochlehnert A, Nikendei C. [Metabolic syndrome and depression]. Ther Umsch 2006; 63:521-527.
128. Kreyenbuhl J, Dickerson FB, Medoff DR, et al. Extent and management of cardiovascular risk factors in patients with type 2 diabetes and serious mental illness. J Nerv Ment Dis 2006; 194:404-410.
129. Gans RO. The metabolic syndrome, depression, and cardiovascular disease: interrelated conditions that share pathophysiologic mechanisms. Med Clin North Am 2006; 90:573-591.
130. Taylor V, Macqueen G. Associations between bipolar disorder and metabolic syndrome: a review. J Clin Psychiatry 2006; 67:1034-1041.
131. Angst F, Stassen HH, Clayton PJ, et al. Mortality of patients with mood disorders: follow-up over 34-38 years. J Affect Disord 2002; 68:167-181.
132. Osby U, Brandt L, Correia N, et al. Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen Psychiatry 2001; 58:844-850.
133. Mcelroy SL, Frye MA, Suppes T, et al. Correlates of overweight and obesity in 644 patients with bipolar disorder. J Clin Psychiatry 2002; 63:207-213.
134. Fagiolini A, Kupfer DJ, Houck PR, et al. Obesity as a correlate of outcome in patients with bipolar I disorder. Am J Psychiatry 2003; 160:112-117.
135. Kilbourne AM, Cornelius JR, Han X, et al. Burden of general medical conditions among individuals with bipolar disorder. Bipolar Disord 2004; 6:368-373.
136. Cassidy F, Ahearn E, Carroll BJ. Elevated frequency of diabetes mellitus in hospitalized manic-depressive patients. Am J Psychiatry1999; 156:1417-1420.
137. Regenold WT, Thapar RK, Marano C, et al. Increased prevalence of type 2 diabetes mellitus among psychiatric inpatients with bipolar I affective and schizoaffective disorders independent of psychotropic drug use. J Affect Disord 2002; 70:19-26.
138. Fagiolini A, Frank E, Scott JA, et al. Metabolic syndrome in bipolar disorder: findings from the Bipolar Disorder Center for Pennsylvanians. Bipolar Disord 2005; 7:424-430.
139. Yumru M, Savas HA, Kurt E, et al. Atypical antipsychotics related metabolic syndrome in bipolar patients. J Affect Disord 2007; 98:247-252.
140. Guo JJ, Keck PE Jr., Corey-Lisle PK, et al. Risk of diabetes mellitus associated with atypical antipsychotic use among Medicaid patients with bipolar disorder: a nested case-control study. Pharmacotherapy 2007; 27:27-35.
141. Isojarvi JI, Rattya J, Myllyla VV, et al. Valproate, lamotrigine, and insulin-mediated risks in women with epilepsy. Ann Neurol 1998; 43:446-451.
142. Pylvanen V, Knip M, Pakarinen AJ, et al. Fasting serum insulin and lipid levels in men with epilepsy. Neurology 2003; 60:571-574.
143. Akiskal HS, Fuller MA, Hirschfeld RM, et al. Reassessing carba-mazepine in the treatment of bipolar disorder: clinical implications of new data. CNS Spectr 2005; 10:(suppl1):11 (discussion 12-3, quiz 14-15).
144. Schmider J, Lammers CH, Gotthardt U, et al. Combined dexamethasone/corticotropin-releasing hormone test in acute and remitted manic patients, in acute depression, and in normal controls: I. Biol Psychiatry 1995; 38:797-802.
145. Cervantes P, Gelber S, Kin FN, et al. Circadian secretion of cortisol in bipolar disorder. J Psychiatry Neurosci 2001; 26:411-416.
146. Elmslie JL, Mann JI, Silverstone JT, et al. Determinants of overweight and obesity in patients with bipolar disorder. J Clin Psychiatry 2001; 62:486-491(quiz 492-3).
147. Dunaif A, Thomas A. Current concepts in the polycystic ovary syndrome. Annu Rev Med 2001; 52:401-419.
148. Joffe H, Cohen LS, Suppes T, et al. Valproate is associated with new-onset oligoamenorrhea with hyperandrogenism in women with bipolar disorder. Biol Psychiatry 2006; 59:1078-1086.